Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or
can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression …

Combination treatment with BRAF (BRAFi) plus MEK inhibitors (MEKi) has demonstrated
survival benefit in patients with advanced melanoma harboring activating BRAF mutations. …

Drug delivery systems can provide enhanced efficacy and/or reduced toxicity for anticancer
agents. Liposome drug delivery systems are able to modify the pharmacokinetics and …

Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint
inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown …

Background Covid-19 pandemic by the new coronavirus SARS-Cov-2 has produced devastating
effects on the health care system, affecting also cancer patient care. Data about COVID-…

Serial analysis of BRAF mutations in circulating-free DNA (cfDNA) could be of prognostic
value in melanoma patients. We collected blood samples from 63 advanced BRAFV600E/K …

Gemcitabine (2′, 2′-difluorodeoxycytidine) is a nucleoside analog with antitumor activity
against a variety of malignancies. The critical enzyme cytidine kinase is saturated at plasma …

A retrospective observational study was conducted on patients diagnosed with serine/threonine-protein
kinase B-Raf (BRAF)‑mutated metastatic melanoma, who underwent first‑line …

Aims and Background Brain metastases are an unusual finding in patients with colorectal
carcinoma. We wished to determine the clinical presentation, the time interval between the …

Cutaneous melanoma is the most aggressive of skin tumors. In order to discover new
biomarkers that could help us improve prognostic prediction in melanoma patients, we have …